Sustainable Bio-based Chemicals Will Capture Asia And Latin America

Key Takeaways

• Focus on sustainable, high-value specialty chemicals and strong innovation positions Ashland for margin resilience and accelerated earnings growth.
  
• Strategic expansion in emerging markets and cost optimization enhances revenue stability and supports above-average growth in resilient end-markets.
  
• Prolonged demand softness, portfolio vulnerability, and diminishing internal cost levers pose lasting challenges to revenue growth, earnings stability, and long-term margin improvement.

Catalysts

Provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally.

• The global shift toward sustainable and bio-based materials-driven by regulatory requirements and consumer preference-continues to gain momentum, benefiting Ashland's specialty chemicals portfolio that is now more focused on high-value, sustainable, and compliant solutions; this is expected to support top-line revenue growth and margin resilience over the long term.
  
• The expanding middle class in emerging markets is fueling demand for personal care and pharmaceutical products, both key end-markets for Ashland. The company is already leveraging its reputation and localized innovation, particularly in Asia and Latin America, positioning it for above-average growth in these high-potential segments and geographies, which should drive revenue and gross margin expansion.
  
• Ongoing strategic cost reductions and manufacturing network optimization are set to deliver meaningful incremental savings ($55–60 million year-over-year expected in FY26), underpinning structurally higher EBITDA margins and improved free cash flow conversion as the benefits phase into the P&L.
  
• Strong commitment to R&D and innovation-demonstrated by successful new launches (e.g., bio-based additives, Viatel injectable polymers, cellulosics for pharma)-is already achieving innovation-driven revenue targets ahead of schedule and should accelerate earnings growth as these differentiated products ramp up commercial adoption.
  
• With 85% of the portfolio tied to noncyclical, resilient consumer end-markets (pharma, personal care), Ashland's more focused business mix enhances revenue stability and pricing power, leaving it well positioned to capture outsized growth and margin gains as global macro and industry-specific demand trends normalize.

Ashland Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Ashland's revenue will grow by 2.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from -44.7% today to 19.9% in 3 years time.
• Analysts expect earnings to reach $394.7 million (and earnings per share of $7.38) by about August 2028, up from $-836.0 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 7.8x on those 2028 earnings, up from -3.0x today. This future PE is lower than the current PE for the US Chemicals industry at 25.5x.
• Analysts expect the number of shares outstanding to decline by 6.4% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.48%, as per the Simply Wall St company report.

Ashland Future Earnings Per Share Growth

Risks

• Ongoing weakness and overcapacity in China and other key export markets, coupled with intense competition and persistent demand softness, continue to pressure volumes and pricing for Specialty Additives; this trend may prove structural and could drive prolonged revenue and margin headwinds.
  
• Ashland's core portfolio is heavily weighted toward Personal Care and Life Sciences, making it vulnerable to shifts in consumer preferences, secular declines in high-end/premium segments, and customer concentration risk; revenue volatility in these segments could persist and impact earnings stability.
  
• The company's portfolio optimization actions-divesting lower-margin or non-core businesses-have improved margins but also structurally lowered revenue, highlighting modest core growth rates and suggesting that further topline acceleration may be challenging without breakthrough innovation; this could limit long-term revenue and EBITDA expansion.
  
• While manufacturing optimization and restructuring are delivering significant cost savings in the near term, productivity gains will become harder to achieve in future years; once current initiatives are fully recognized, Ashland may face difficulty finding new internal levers for margin or free cash flow improvement beyond organic top-line growth.
  
• Impairment of $706 million in goodwill, driven by the decline in market capitalization relative to book value and sector valuation compression, signals the market's skepticism about Ashland's sustainable growth trajectory and could foreshadow further pressure on long-term return on invested capital and net earnings if secular or company-specific challenges persist.

Valuation

• The analysts have a consensus price target of $65.111 for Ashland based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $79.0, and the most bearish reporting a price target of just $53.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $2.0 billion, earnings will come to $394.7 million, and it would be trading on a PE ratio of 7.8x, assuming you use a discount rate of 8.5%.
• Given the current share price of $54.88, the analyst price target of $65.11 is 15.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.